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Perhaps the most urgent question is whether soluble
ACE2 (sACE2), and various fusion constructs or frag-
ments, can serve as potent inhibitors of the virus infec-
tion in vivo. The analogy to HIV could help to avoid
costly clinical trials and save time. After the failure of
recombinant soluble CD4 (sCD4) to affect HIV replication
in humans, it took more than a decade to develop a
potent multivalent CD4-IgG fusion protein, which is now
showing promising results in recent clinical trials. Like
sCD4, sACE2 is likely to have a short half-life in vivo,
and may not be a very potent inhibitor in a monovalent
form. Multivalent sACE2-immunoglobulin proteins might
be much better inhibitors of SARS-CoV infection in vivo
than sACE2. Antibodies, other proteins, and perhaps
peptides and small molecules disrupting the ACE2 inter-
action with the S glycoprotein could also be viable tools
in the treatment of SARS-CoV infections (although exist-
ing ACE inhibitors are unlikely to be useful). The solution
of the crystal structure of the receptor and its complex
with receptor binding fragments of S1 will provide a
detailed understanding of its interactions with the viral
protein and could help in the development of such inhibi-
tors. Finally, soluble forms of the S glycoprotein ectodo-
main, the RBD, and even receptor-bound conformations
of the S glycoprotein may have potential as vaccine
immunogens that elicit neutralizing antibodies; such re-
ceptor-bound conformations of the HIV-1 gp120 have
been recently proposed as vaccine immunogens that
could elicit potent broadly neutralizing antibodies. The
rapid pace of research and the acute self-limiting nature
of the SARS-CoV infection (unlike HIV infection) could
lead to significantly faster development of therapeutics
and vaccines than for HIV, and this could be another
unexpected but welcome surprise.
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